Search

Your search keyword '"P2Y12 Receptor Antagonists"' showing total 208 results

Search Constraints

Start Over You searched for: Descriptor "P2Y12 Receptor Antagonists" Remove constraint Descriptor: "P2Y12 Receptor Antagonists"
208 results on '"P2Y12 Receptor Antagonists"'

Search Results

51. Efficient removal of apixaban with extracorporeal hemoadsorption

52. Research on P2Y12 Platelet Inhibitors Described by Researchers at University of Chicago (Abstract Number - 98: Intravenous dose-adjusted cangrelor use for neuroendovascular procedures: An institutional experience).

53. Abstract 14931: Low-Dose Prasugrel Has Prognostic Superiority to Clopidogrel in High-Bleeding Risk Patients Undergoing Contemporary Percutaneous Coronary Intervention

54. Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis

55. Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach

56. Gender in non- ST elevation myocardial infarction and unstable angina: is there any equality?

57. Do we need a new P2Y12 receptor antagonist?

58. Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry

59. Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction

60. Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration

61. Does Ticagrelor Improve Endothelial Function?

62. Is ticagrelor worth its high cost and side-effects?

63. Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond

64. Northwestern University Researchers Have Provided New Study Findings on Intracranial Hemorrhages (Abstract 1122-000210: Cangrelor to Prevent Intraluminal Thrombosis in Endovascular Therapy for Acute Stroke: Single Center Case Series).

65. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.

66. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.

67. The role of oral anticoagulant therapy in patients with acute coronary syndrome

68. Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction

69. P329Residual platelet reactivity after pre-treatment with ticagrelor prior to primary percutaneous coronary intervention is associated with suboptimal myocardial reperfusion

70. 463Temporal trends in latecomer ST-segment elevation myocardial infarction patients: Insights from the AMIS Plus Registry 1997–2017

71. P1764Quality criteria for STEMI care - a national perspective

72. Annals for Hospitalists - 17 September 2019

73. Ticagrelor-Associated Shift From Obstructive to Central Sleep Apnea: A Case Report

74. Sinoatrial Arrest Caused by Ticagrelor after Angioplasty in a 62-Year-Old Woman with Acute Coronary Syndrome

75. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.

76. SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME

77. The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy

78. Risk guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses

79. Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program

80. Excess mortality and guideline-indicated care following non-ST-elevation myocardial infarction

81. Antiplatelet Therapy in Percutaneous Coronary Intervention

82. A Case Series of 18 Patients Receiving Ticagrelor After Carotid Stenting

83. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease

84. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention

85. A Sticky Situation: Poor Correlation Between Platelet Inhibition Assays

86. Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?

87. Ticagrelor-induced dyspnoea

88. Efficacy of P2Y12 receptor antagonists in patients with atrial fibrillation according to the CHA2DS2VASc score

89. Ticagrelor and Central Sleep Apnea

90. A223 FACTORS ASSOCIATED WITH EUS DIAGNOSTIC YIELD AND ADVERSE EVENT RISK: A LARGE RETROSPECTIVE SINGLE CENTRE STUDY

92. Pharmacosimulation of interruptions and its solution in intravenous administration of cangrelor

93. The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions

95. Efficacy of Change to New P2Y12 Receptor Antagonists in Patients High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention

96. Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers

97. Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting

98. GW29-e1128 Comparison of Dual Antiplatelet Therapy with Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome at High Risk of Bleeding

99. Lack of Correlation Between Verifynow and TEG-Platelet Mapping in Ventricular Assist Device Patients

100. Is Long-Acting P2Y 12 Receptor Antagonist Therapy Ideal in Patients With Recently Implanted Drug-Eluting Stents in Need of Mechanical Circulatory Support?

Catalog

Books, media, physical & digital resources